Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial

Table 2

The changes in concentrations of soluble inflammation markers between days 0–5 and 0–14. Median (range).

Marker	APC; baseline; 𝑛=16	Placebo; baseline; 𝑛=16	𝑃-value	APC; change 0–5 d; 𝑛=14	Placebo; change 0–5 d; 𝑛=13	𝑃-value	APC; change 0–14 d; 𝑛=11	Placebo; change 0–14 d; 𝑛=11	𝑃-value
IL-8, pg/mL	286; (56.4–1760)	245; (41.5–1750)	0.867	−72.3; (−1630–60.8)	−39.5; (−275–470)	0.159	−84.9; (−266–263)	−132; (−1280–−50.4)	0.270
IL-6, pg/mL	798; (93–7190)	643; (235–41800)	1.000	−377; (−1350–−1090)	−517; (−41600–−182)	0.159	−724; (−1550–979)^5	−884; (−41700–−388)	0.288
IL-1ra, pg/mL	4480; (143–107000)	2870; (656–12400)	0.590	−2210; (−20500–2160)	−1480; (−1150–−6380)	0.627	−1500; (−7850–3950)	−750; (−3890–2240)	0.243
IL-10, pg/mL	13.7; (2.78–367)	10.8; (4.17–145)	0.724	−5.51; (−28.9–6.04)	−6.72; (−137–28.1)	0.438	−6.70; (−33.2–72.1)	−6.20; (−139–77.0)	0.898
sE-selectin, ng/mL	41.4; (25.3–195)	86.1; (19.0–192)	0.445	0.06; (−139–20.0)	−40.5; (−135–16.9)	0.099	0.100; (−143–14.4)	−45.6; (−144–8.70)	0.270
PCT, ng/mL	1.03; (0.12–8.33)^1	0.75; (0.18–3.96)^2	0.880	0.18; (−7.53–3.47)^3	−0.21; (−1.91–1.62)^4	0.590	0.130; (−4.66–3.96)	−0.270; (−3.30–2.09)^6	0.918

¹𝑛=14, ²𝑛=15, ³𝑛=11, ⁴𝑛=10, ⁵𝑛=12, ⁶𝑛=10.
d: day; IL: interleukin; PCT: procalcitonin.
𝑃-values are calculated for differences between the two groups in changes from baseline.